Exchange: NASDAQ·Updated 07:30 PM EST
ARDX logo

ARDX Ardelyx Inc

$3.09
$0.02
(0.65%)
Today
Closed $3.07
$0.02
(0.65%)
After Hours
Reported EarningsNov 3
Mkt Cap$776.74M
Vol3.8M

About ARDX

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
44

Bearish Sentiment

How do you feel about ARDX?

M_OF_E
$ARDX Ibsrela- TRx strong 4 week change, Total Patients(4 week total) second highest of the year. October TRx was about 4.5% above the 3rd quarter average. The 4 week change while very strong was off a weaker number so TRx was good for the week about 2.5% above 3rd quarter average. NRx and RRx about what you would expect no real surprises. NRx not quite as strong as in late September when it was extremely strong but not weak by any means. Xphozah TRx down slightly on a 4 week change but still in the same zone, above last year below the Mid-Feb to June strength. October was around 8% above 3rd quarter average so reasonable strength there. Again NRx and RRx about what you would expect no surprises.
86
M_OF_E
$ARDX According to Bloomberg 10 out the 11 analysts that cover ARDX reiterated their recommendations either yesterday or today,
1
54
FerreroRocher
$ARDX The United States Patent and Trademark Office notified the Company that on November 10, 2026, they will issue U.S. Patent No. 12,788,750 titled, "Oral Formulation of a Therapeutic Compound", with an expiration date of December 6, 2041. This patent will cover the Company's commercial formulations of both IBSRELA and XPHOZAH.
1
46
Kwash21
$ARDX Blackrock increased their holding by 4.9 million shares in q3 now hold 28.4 million shares (11.3 % ownership). Rubric still not reported.
1
34
M_OF_E
$ARDX Ibsrela- TRx down on a 4 week change from a very strong number. TRx a little over 2.5% above the 3rd quarter average. So from a 4 week change basis a little disappointing but still over the 3rd quarter average so Okay. Total Patients(4 week sum) slightly above 3rd quarter average. NRx not quite up with the very strong numbers from late last quarter, in fact 4 weeks ago was the strongest NRx this year so that is what reduced the 4 week change. RRx maybe a little stronger than the other 2 since it was up from 4 weeks before. So while I prefer to see positive 4 week TRx changes, it was above the 3rd quarter average. Xphozah. TRx basically unchanged from 4 weeks before but about 5% above the 3rd quarter average. NRx weak compared to recent strong numbers, RRx strong compared to recent numbers. So still below the very strong numbers in Mid-Feb- June but above the 3rd quarter average. Caveat/overview in replies
41
opportoni
$ARDX Those who’ve been here longer might recall my cautious approach regarding the oral formulations patent. At the time, the patent primarily claimed a production process which offers weaker protection than a patent on the formulation itself. This has been rectified with the newly issued divisional application US2026158022 which now includes a claim on the actual formulation. Issue notification was mailed on October 28. This is great news IMHO.
41
Chasse_patate
$ARDX If the CEO of ARDX had to resign because of multiple affairs, including an affair with a Chinese spy, the stock price would instantly go up by 50%.
31
Kwash21
$ARDX Put option firm revealed, Caption Management, puts for 9.4 million shares and increased position from 100k shares to 4.1 million.
20
Bear0927
$ARDX So, Profitability in 2027 with a P/S< 2 currently. IBSRELA demand remains. CIC coming in ahead of schedule. XPHOZAH still has optionality. Patent moat beefed up for the entirety of the 2030s. Political will to address Kidney Care in America is directionally bullish. The market may not like ARDX, but I do (so do analysts apparently, not that I place a lot of stock in them). Sometimes at night I stare at the ceiling and wonder why Mott hasn't bought shares. Then I chuckle and roll over and fall asleep. I sleep peacefully. Looking forward to the climb.
34
zeromnil
$ARDX After years and years of holding, I have unfortunately had to divest my shares. Monday morning when this thing rockets to 200 a share, I expect at least a fruit basket, or greeting card.
29
zerotomil
$ARDX Tang bought 9M shares at an average of 4.65. Tang has a history of shareholder activism but at 3.66% ownership not big enough to effect a change at the moment. If he is planning to do something similar to what he did at AUPH then this is probably just a starter position - will probably build on it and eventually lead to a management change.
17
DoctorZebra
$ARDX he United States Patent and Trademark Office notified the Company that on November 10, 2026, they will issue U.S. Patent No. 12,788,750 titled, “Oral Formulation of a Therapeutic Compound”, with an expiration date of December 6, 2041. This patent will cover the Company’s commercial formulations of both IBSRELA and XPHOZAH.
29
Paul_Volcker
$ARDX Now that it seems they have stopped the bleeding I am going to be very interested to see if Uncle Mott comes in and adds to his holdings. There are never any guarantees in this game but it seems like the worst may be behind us so a purchase down here is relatively safe IMO. If no purchase happens in the next couple of weeks - that will be an interesting data point for me. Time will tell. I would love to see any valuation spreadsheets that Morgan Stanley may have created.
1
25
Cameohitch
$ARDX Playing that Ibsrela commercial on repeat before the call started was a nice touch IMHO.
26
wildcard55
$ARDX I am admittedly relieved. Ha gonna feel like a long wait until February, but at least the longer term thesis remains intact in the meantime. Ardy has two great drugs that are well-liked by patients and doctors. Just gotta keep going getting the drugs into the hands of more people and hope the political and regulatory environment throws us a bone.
26
opportoni
$ARDX I have not bought any in a while, but I will now start to accumulate more again. $2.88 is just too low. Even if one considers Xphozah nothing but a burden, there is always the chance to sell it cheap or write it off (preferably after collecting many millions in TDAPA payments). For Ibsrela there will always be some market. In the worst case, they‘d have to cut prices and/or spending and they could still operate this at decent profits. Market is terribly wrong on this one.
25
nick39
$ARDX Rubric Capital's Q3 13F filing is due by the end of today, and we'll finally learn whether David Rosen increased Rubric's ARDX position during July–September.
15
Burning_Cash
$ARDX 2027 will see Ibsrela growth rates increase vs. 2026 IMHO. Let’s focus on the IBSRELA Pharmacy Network (IPN) as to why. 1. More patients actually get access to Ibsrela. Lower prescription abandonment numbers result in a higher conversion rate for the same number of patients prescribed Ibsrela. 2. Prescriptions filled through IPN result in at least 1 additional refill per patient. On 5-6 refills per patient per year currently, that’s huge growth baked in. 3. Patient churn, as per management, is lower for IPN-prescriptions, therefore fewer new patient starts are needed to replace those who stopped using Ibsrela for whatever reason. 4. A seamless IPN experience could lower the threshold for doctors to prescribe Ibsrela. Now, we don’t know which percentage of patients is funnelled through IPN, but it’s a stated strategic priority for the company, so I believe that percentage will substantially increase. NIA, but I believe IPN’s a flywheel for growth that the market’s underestimating.
24
Burning_Cash
$ARDX Listening to Steve Eisman (from “The Big Short” fame) on AI right now. He mentions only 2 sectors that are not, in his view, tied to the bubble: staples and healthcare. Not even bonds offer security, because much of those are tied, directly or indirectly, to AI doing well as well now. We should see investors flock to healthcare at some point in the not too distant future IMHO. Companies making money, or having a clear path to profitability, will become a thing investors will start to value again. Shocking, I know.
20
RBR88
$ARDX lol so big pharma can buy this and cut in half general expenses and have 15 years of free cash flow ... Bring that cash flow at 14% if you want because of the risk. The normal range is 8% to 14% but let's assume the highest... Cash on hands pays the debt and assuming zero value at patent expiration. I still get a present value of 10$ .... Well a range from 8$-12$.... This has to go up IMO within next year
1
21

Advertisement|Remove ads.